Pancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis. However, treatment of PC in high-volume centers with the support of a multidisciplinary approach has widely demonstrated improvement both in terms of short- and long-term outcomes. The recent worldwide spread of Covid-19 pandemic significantly affected the healthcare systems of most countries in the world, particularly in red areas such as Italy, with more than 100.000 cases in a two-month time lapse. This inevitably reflected in a reorganization of hospital activities, including the diagnostic and therapeutic pathways for PC treatment. With the aim of giving an objective and real representation of the impact of Covid-19 on PC treatment, the investigator here propose a multicenter Italian observational study comparing a 6-month period before and during the Covid-19 pandemic. Only high-volume centers will be involved in the study. A comparison between the general, clinical, endoscopic and surgical outcomes will be performed by means of a global and month-by-month analysis between the two study periods.
Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
Inclusion Criteria:
all patients with a diagnosis of pancreatic cancer referred to one of the centers involved
in the study during the two study periods
Exclusion Criteria:
- patients under the age of 18
- inability to give informed consent
Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma
Roma, Lazio, Italy